HomeTrialNCT05047094
🔬NCT05047094NARECRUITING

Alpha Radiation Emitters Device (DaRT) in Combination With Check Point Inhibitor for the Treatment of Recurrent Unresectable or mHNSCC

Study Summary

A unique combinational treatment for cancer employing intratumoral diffusing alpha radiation emitter device with check point inhibitor for recurrent unresectable or metastatic Head and Neck Squamous Cell Carcinoma

View on ClinicalTrials.gov ↗
Study Details
Enrollment48 participants
Primary Completion
Lead SponsorAlpha Tau Medical LTD.
Data Retrieved2026-06-17 02:56:49.846179+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.